AC Immune Partner LMI progresses Tau PET Tracer PI-2620

  • AC Immune’s Tau PET tracer is one step closer to becoming a next-generation diagnostic for Alzheimer’s disease (AD)
  • AC Immune will receive milestone payment from LMI to advance late-stage product development

LAUSANNE, Switzerland, Sept. 26, 2022 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its partner, Life Molecular Imaging (LMI), advances PI-2620, the Tau positron emission tomography (PET) tracer, into late-stage clinical development in Alzheimer’s disease (AD). As part of the agreement with AC Immune, LMI will make a milestone payment.

PI-2620 is a potentially best-in-class Tau PET tracer with high binding affinity and selectivity for aggregated Tau. Proprietary morphomer of AC Immune® led to the discovery of PI-2620 as part of a research collaboration with LMI. Tau aggregates are an important indicator of neuronal death and are strongly correlated with cognitive decline. Accurate detection of aggregated Tau may therefore contribute to improved diagnosis and advanced monitoring of cognitive performance in patients with dementia.

Results supporting the use of PI-2620 in patients with Alzheimer’s disease were obtained from an investigator-sponsored Phase 2 trial at Asan Medical Center and were presented this year at the Alzheimer’s Association International Conference (AAIC). This study involving 69 subjects showed the relevance of using PI-2620 as a targeted radiopharmaceutical for the detection of Tau deposits and to measure longitudinal changes in subjects with mild cognitive impairment (MCI) and in patients with MY.1

Further details on upcoming clinical developments will be available on clinicaltrials.gov and reported at upcoming scientific meetings.

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “The excellent imaging properties of PI-2620 in patients with AD highlight the ability of AC Immune’s Morphomer® platform to generate small molecules penetrating into the brain and cells capable of binding to intracellular pathological proteins such as Tau. Additionally, unlike most Tau PET tracers that have only been shown to be effective in AD, PI-2620 also appears to be a potentially useful tool for non-AD tauopathies such as PSP and CBD, making it potentially best in class and enables patient identification for earlier treatment. The continued clinical development of this next-generation diagnostic is an important step in our efforts to prevent disease progression with targeted therapies, such as mid-stage and late-stage clinical therapeutic candidates in our therapeutic pipeline.

Dr. Andrew Stephens, MD, Ph.D., Chief Medical Officer at LMI added: “We are very encouraged by the Phase 2 data presented to AAIC as part of the ongoing assessment in AD and non-AD tauopathies. We look forward to further development of PI-2620 as a potentially best-in-class Tau PET tracer in AD patients. The availability of a reliable diagnostic agent to visualize disease development in patients with AD is critical to the successful clinical development of disease-modifying products. In short, PI-2620 has the potential to become a diagnostic capable of identifying AD and other tauopathies at the earliest stage, more accurately selecting stage-specific clinical study subjects, and ultimately , to monitor the effects of treatment.

References

  1. Minyoung Oh et al.; One-year longitudinal variation of Tau accumulation on [18F]PI-2620 PET in the Alzheimer spectrum; Presentation of virtual posters; AAIC 2022

About PI-2620
PI-2620 was discovered and developed using the Morphomer® As part of a research collaboration between AC Immune and LMI, LMI holds the exclusive worldwide license to research, develop and commercialize the Tau PET tracers generated under the discovery program. It has demonstrated robust cerebral uptake and rapid washout in non-target regions, a wide imaging window between 30 and 90 minutes post injection (pi) for AD, and excellent reproducibility between test and retest analyzes . The absence of significant off-target binding allows PI-2620 to detect and quantify early Tau deposition in the brain.
PI-2620 is currently undergoing several clinical studies as a targeted radiopharmaceutical for the detection of Tau deposits in the human brain. PI-2620 also shows promise for non-AD tauopathies like progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS).

About AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomere®, fuel its broad and diverse portfolio of blue-chip and blue-chip assets, which currently includes ten therapeutic candidates and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, including Roche Group member Genentech, Eli Lilly and Company and Janssen Pharmaceuticals, Inc., which has resulted in securing unrestricted funding. substantial dilution to advance its proprietary programs. and > $3 billion in potential milestone payments.
SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU and SG. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, NO and RU.

About Life Molecular Imaging (LMI)
Life Molecular Imaging (LMI, formerly Piramal Imaging) was established in 2012 with the acquisition of Bayer Pharma AG’s molecular imaging research and development portfolio. It is now part of Alliance Medical Group (a member of Life Healthcare Group) offering an integrated business including research and development laboratories, a cyclotron network, radiopharmacies and imaging facilities. By developing new PET tracers for molecular imaging, LMI is focusing on a key area of ​​modern medicine. The organization strives to be a leader in the field of molecular imaging by developing innovative products that improve the early detection and characterization of chronic and life-threatening diseases, leading to better treatment outcomes and improved better quality of life. Please visit https://life-mi.com.

For more information, please contact:

Forward-looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than statements of fact. historical records and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may”, “could”, “shall”, “should”, “expect”, “plan”, “anticipate”, “believe”, “valued”. ,” “predicted”, “plans”, “potential”, “outlook” or “continuing” and other comparable terms. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by such statements.These risks and uncertainties include those described under “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Outlook” of AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, our suppliers, our patients and our employees and any other impacts of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not assume any obligation to update them in light of new information, future developments or otherwise, except as required by applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.